HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Read responses to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deyo, R A Search for Related Content PubMed PubMed Citation Articles by Deyo, R A

Bruce Psaty and the risks of calcium channel blockers

Department of Medicine, Department of Health Services, and Center for Cost and Outcomes Research, University of Washington, Seattle, WA 98195, USA; deyo@u.washington.edu

Keywords: Bruce Psaty; calcium channel blockers

The first 150 words of the full text of this article appear below.

On a fine March day in 1995 Dr Bruce Psaty ascended the podium to present a scientific paper as he had many times before. At a hotel in San Antonio he was speaking before the Epidemiology and Prevention Council of the American Heart Association, a small meeting of academic researchers. Psaty and his colleagues had been studying complications associated with drugs for treating hypertension. The paper seemed innocuous. "It was merely an observational study, so it was unlikely to be seen as important or controversial", he says. But a hostile question and answer session presaged a relentless attack from drug manufacturers. And the apparent controversy piqued the interest of journalists attending the meeting.

Psaty had found that a class of relatively new and expensive drugs—calcium channel blockers—was associated with a higher risk of myocardial infarction than older less expensive drugs.¹ This was especially true for short acting calcium channel drugs. . . . [Full text of this article]

This article has been cited by other articles:

				D Neuhauser The Heroes and Martyrs series: job descriptions for health care quality improvement professionals? Qual. Saf. Health Care, August 1, 2005; 14(4): 230 - 230. [Full Text] [PDF]

				L M Santiago, S M Debanne, and D Neuhauser Tracking adverse events in RCTs: lack of agreement among regulatory institutions Qual. Saf. Health Care, June 1, 2003; 12(3): 234 - 234. [Full Text] [PDF]

eLetters: